Global

Nine months on from the 2016 EFPIA Disclosure Code deadline - requiring all member companies across Europe to publish their data concerning their transfer-of-value transactions to HCPs - EFPIA's Andrew Powrie-Smith offered an update on media and industry responses.

The EMA released the revised Module V- Risk Management Systems (Rev 2) of Good Pharmacovigilance Practice (GVP) (EMA/838713/2011 Rev 2) accompanied by a revised Guidance on the format of the risk management plan (RMP) in the EU.

It is hard to resist the sensation that the rhetoric of Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.

A conversation with Tommy Fanning, head of biopharma at IDA Ireland, about the country’s growth as a manufacturing powerhouse-and its bid to attract UK-based EMA post-Brexit.

Is the Greek pharmaceuticals and healthcare sector, once a strong bridge between Europe and the East, on the mend after suffering the recent ravages of the global financial crisis and subsequent austerity policies?

March 28, 2017

March 28, 2017

March 27, 2017

March 24, 2017

March 20, 2017

While it is foundational to commercial operations, most European life sciences companies are not getting what they need from their customer data, writes Guillame Roussel.

March 20, 2017

It is hard to resist the sensation that the rhetoric of that Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.

NICE and NHSE have been grappling with the issue of affordability. It’s not a new challenge, but with the advent of new treatments that are both cost effective and unaffordable, something has to be done. Leela Barham reports.

Pharm Exec talks to Hugo Fry, Sanofi’s General Manager for the UK and General Manager for Sanofi Pasteur UK and Ireland, about his vision for the company and the vaccine space in these markets.

March 07, 2017

The European Commission's latest economic assessment of EU member states does not make for comfortable reading, writes Reflector.

Pharm Exec speaks to Chris Molloy, CEO of the newly established Medicines Discovery Catapult, which aims to establish new approaches to grow and sustain the UK's reputation for innovative, fast-to-patient drug discovery.

March 03, 2017

Leela Barham looks at NICE's new position statement, which seeks to set out a little more clearly how it works with industry.

March 01, 2017

March 01, 2017

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

February 28, 2017

With a population of just 4.7 million and a landmass smaller than the state of Indiana, the republic of Ireland stands as an unlikely pharmaceutical manufacturing powerhouse.

February 23, 2017

February 22, 2017

February 22, 2017

Global market access analyst Neil Grubert discusses what are likely to be some of the key trends in market access this year and beyond, and the implications for the life sciences industry.